NewAmsterdam Pharma (NAMS) Current Deferred Revenue (2022 - 2026)

NewAmsterdam Pharma (NAMS) has 5 years of Current Deferred Revenue data on file, last reported at $4.0 million in Q1 2026.

• For the quarter ending Q1 2026, Current Deferred Revenue rose 31.58% year-over-year to $4.0 million; the trailing twelve-month figure through Mar 2026 stood at $4.0 million (up 31.58% YoY), and the FY2025 full-year result was $4.0 million, down 33.64% from the prior year.
• Current Deferred Revenue was little changed at $4.0 million in Q1 2026, from $4.0 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $13.3 million in Q4 2022 to a low of $10551.7 in Q2 2023.
• A 5-year average of $5.9 million and a median of $5.3 million in 2024 frame the typical range for Current Deferred Revenue.
• Across the five-year window, Current Deferred Revenue surged 57322.15% in 2024 and sank 62.67% in 2025, its largest moves.
• Tracing NAMS's Current Deferred Revenue over 5 years: stood at $13.3 million in 2022, then declined by 24.94% to $10.0 million in 2023, then slumped by 39.68% to $6.0 million in 2024, then tumbled by 33.64% to $4.0 million in 2025, then changed by 0.0% to $4.0 million in 2026.
• Business Quant data shows NAMS's Current Deferred Revenue at $4.0 million in Q1 2026, $4.0 million in Q4 2025, and $3.0 million in Q1 2025.